US20050124051A1 - Hydroxylation of compactin to pravatatin by micromonospora - Google Patents
Hydroxylation of compactin to pravatatin by micromonospora Download PDFInfo
- Publication number
- US20050124051A1 US20050124051A1 US11/014,658 US1465804A US2005124051A1 US 20050124051 A1 US20050124051 A1 US 20050124051A1 US 1465804 A US1465804 A US 1465804A US 2005124051 A1 US2005124051 A1 US 2005124051A1
- Authority
- US
- United States
- Prior art keywords
- pravastatin
- compound
- formula
- micromonospora
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000187708 Micromonospora Species 0.000 title abstract description 17
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 title description 21
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 title description 20
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 title description 20
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 title description 20
- 238000005805 hydroxylation reaction Methods 0.000 title description 8
- 230000033444 hydroxylation Effects 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 239000000758 substrate Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 230000007483 microbial process Effects 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 4
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 235000015097 nutrients Nutrition 0.000 claims abstract description 3
- 238000000746 purification Methods 0.000 claims abstract description 3
- 229960002965 pravastatin Drugs 0.000 claims description 74
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 71
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000000640 hydroxylating effect Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 abstract description 2
- 238000010564 aerobic fermentation Methods 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 239000002609 medium Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- -1 meliblose Chemical compound 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 241000187722 Micromonospora echinospora Species 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 239000000049 pigment Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 150000002596 lactones Chemical group 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- 241000187723 Micromonospora sp. Species 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 239000003610 charcoal Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- OQARDMYXSOFTLN-PZAWKZKUSA-N pravastatin lactone Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 OQARDMYXSOFTLN-PZAWKZKUSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000002024 ethyl acetate extract Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 5
- 241000218923 Micromonospora megalomicea Species 0.000 description 5
- 241000218940 Micromonospora rosaria Species 0.000 description 5
- 235000019764 Soybean Meal Nutrition 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 5
- 239000004455 soybean meal Substances 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 241001446247 uncultured actinomycete Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- YICSUUMFJQKYCA-SOWWUCBVSA-N [H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=CCC[C@H](OC(=O)[C@@H](C)CC)[C@@]21[H])C[C@@H](O)CC Chemical compound [H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=CCC[C@H](OC(=O)[C@@H](C)CC)[C@@]21[H])C[C@@H](O)CC YICSUUMFJQKYCA-SOWWUCBVSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 3
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000178285 Streptomyces carbophilus Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IOGXUPUEYLGSAS-UHFFFAOYSA-N 2-phenylacetic acid;propan-2-one Chemical compound CC(C)=O.OC(=O)CC1=CC=CC=C1 IOGXUPUEYLGSAS-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000187362 Actinomadura Species 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000938054 Streptomyces lanatus Species 0.000 description 1
- 241000946782 Streptomyces resistomycificus Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000187175 Streptomyces violaceus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000007613 bennett's agar Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- BOZILQFLQYBIIY-INTXDZFKSA-N mevinic acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)CCC=C21 BOZILQFLQYBIIY-INTXDZFKSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/29—Micromonospora
Definitions
- the present invention relates to a new microbial process for the preparation of pravastatin.
- this invention relates to a microbial process for the preparation of pravastatin of formula (I) from a compound of the general formula (II) wherein R stands for an alkali metal or ammonium ion, with a microorganism, wherein said microorganism is a prokaryote from genus Micromonospora , which is able to hydroxylate a compound of the general formula (II) at the 6 ⁇ position.
- the hypercholesterolaemia has been recognized as a major risk factor for atherosclerotic disease, specifically for coronary heart disease.
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMG-CoA reductase EC. 1.1.1.34
- Mevinolin and related compounds biosynthesised by selected strains of different fungal species were found to be competitive inhibitors of this enzyme [Endo, A. et al., J. Antibiotics 29, 1346-1348 (1976); Endo, A. et al., FEBS Lett. 72, 323-326 (1976): Kuo, C. H. et al., J. Org. Chem. 48, 1991-1998 (1983)].
- Pravastatin is also a member of the family of HMG-CoA reductase inhibitors. At first, pravastatin was found as a minor urinary metabolite of compactin in dog (Tanaka, M. et al., unpublished) in the course of metabolic studies of compactin [Arai, M. et al. Sankyo Kenkyusho Nempo, 40, 1-38 (1988)].
- pravastatin as the hydroxylated product of compactin is its tissue selectivity. This drug strongly inhibits sterol synthesis in liver and in intestine, but weakly in other organs. It is advantageous that pravastatin possesses lower toxicity than the other HMG-CoA reductase inhibitors.
- Substrate mycelium is composed of well developed, more curved than straight, monopodially branching filaments. Spores on the sporophores are single, spherical approximately 1.8 ⁇ m in diameter and dispersing more or less evenly on hyphal filaments. Spores are either sessile or on the end of short sporophores. In broth cultures spores were not observed on the hyphae presumably because the release of mature spores is very quick.
- Carbon source utilization Good growth on and positive utilization of L-arabinose, D-galactose, D-fructose, D-glucose, D-xylose, lactose, meliblose, sucrose, D-mannitol, dulcitol, glycerol and inositol. Growth with L-rhamnose, D-raffinose and inulin was slightly better than on the negative control medium.
- Nitrogen source utilization Good growth with yeast extract and NZ-Amine, no or weak utilization of NaNO 3 .
- This strain No. IDR-P 3 of Micomonospora sp. was isolated from a mud sample of Lake Balaton (Hungary).
- This strain produces mostly solitary sporophores and sphaerical dark brown to black spores (0.8-1.5 ⁇ m in diameter) which adhere firmly to the sporophores until maturation. According to our electronmicroscopic observations, on the surface of these spores warty structures or outgrowths (“blunt spines” according to the Vol. 4 of Bergey's Manual of Syst. Bact 1989, pages 2448) can be observed, which is very characteristic of the spores of Micromonospora echinosora . Otherwise, the cultural-morphological and physiological diagnostic properties of this strain are also very similar to those of the M. echinospora . The colour of the well developed colonies on the standard diagnostic media is orange-brown or dark purple.
- the sporulating layer is black or purplish black, waxy.
- Aerial mycelium absent. Melanin pigment not produced. Milk digested. Good growth on D-xylose, D-arabinose, D-glucose, and sucrose, but no growth with L-rhamnose, raffinose, D-galactose, D-fructose, D-meliblose and glycerol. We consider this strain as a typical member of Micromonospora echinospora.
- the orange or orange red colonies consist of long branched filaments (appr. 0.6 ⁇ m in diameter) and a limited number of solitary, sphaerical, dark coloured spores (0.6-1.0 ⁇ m in diameter). Does not produce aerial mycelium. In certain media weak reddish or rose coloured soluble pigments are formed. On tyrosine agar melanold pigments were not produced.
- strain No. IDR-P 7 was identified as a typical member of Micromonospora rosaria (Horan and Brodsky, 1986).
- NCAIM (P) B 001274 Based on the above the invention relates to a new microbial process for the preparation of pravastatin of formula (I) from a compound of general formula (II), wherein R stands for an alkali metal or ammonium ion, by the submerged cultivation of a strain which is able to 6 ⁇ -hydroxylate a compound of formula (II) in aerobic fermentation and by the separation and purification of the compound of formula (I) formed in the course of the bioconversion comprising the steps of
- the scope of the invention extends to the wild strains and any mutants of species belonging to the genus Micromonospora which are able to hydroxylate the sodium salt of the acid form of compactin to pravastatin.
- pravastatin is produced with a Micromonospora strain selected from the group consisting of Micromonospora sp. IDR-P 3 [NCAIM (P) B 001268], Micromonospora purpurea IDR-P 4 [NCAIM (P) B 001271 ], Micromonospora echinospora IDR-P 5 [NCAIM (P) B 001272 ], Micromonospora megalomicea IDR-P 6 [NCAIM (P) B 001273] and Micromonospora rosaria IDR-P 7 [NCAIM (P) B 001274].
- a Micromonospora strain selected from the group consisting of Micromonospora sp. IDR-P 3 [NCAIM (P) B 001268], Micromonospora purpurea IDR-P 4 [NCAIM (P) B 001271 ], Micromonospora echinospora IDR-P 5 [NCAIM (
- pravastatin is produced with Micromonospora sp. strain IDR-P 3 [NCAIM (P) B 001268].
- the present invention can be carried out by in situ fermentation method, that is when, hydroxylation is accomplished with the participation of an actively growing Micromonospora culture.
- the hydroxylation may be conducted by employing agitation as shake-flask culture or aeration and agitation in fermentors, when the compound of the formula (II) is added to the growing cultures.
- an anti-foaming agent may be employed.
- the adequate density of culture of this strain could be achieved by the use of an appropriate medium containing available carbon and nitrogen sources, inorganic salts as well as trace elements.
- glucose, glycerol, dextrin, starch, rhamnose, xylose, sucrose and soluble starch proved to be assimilable carbon sources while soybean meal, corn steep liquor, peptone, yeast extract, meat extract, ammonium citrate and ammonium sulfate as good nitrogen sources.
- Inorganic salts such as calcium carbonate, sodium phosphates, potassium phosphates etc., may be added to the culture medium.
- Preferred media for the growth of this selected strain are those described in the examples.
- the bioconversion of compactin to pravastatin can be done by different fermentation techniques, e.g., batch culture, fed-batch culture.
- a agitated liquid submerged culture is used.
- the preferred temperature is about 25° C. to 37° C., most preferably about 25° C. to 32° C.
- the preferred pH is about 6.0 to 9.0, most preferably about 7.0 to 8.5.
- the preferred shaking condition is about 200 rpm to 400 rpm, most preferably about 250 rpm.
- the invention provides a method for converting compactin acid sodium salt to pravastatin.
- Compactin acid sodium salt can be used in this invention at any concentration which will result in production of pravastatin.
- the compactin concentration is between 0.1 and 10 g/liter, more preferably is between about 0.3 and 3.0 g/liter.
- the invention is meant to cover any percentage of conversion of compactin to pravastatin by the strains of Micromonospora spp., at least 30% and most preferably at least about 90%.
- composition of the culture broth is controlled by a high performance liquid chromatographic (HPLC) method.
- HPLC high performance liquid chromatographic
- pravastatin any known method can be used for the isolation of pravastatin, e.g., extraction-reextraction, anion exchange chromatography, precipitation.
- pravastatin is formed in its acidic form, thus it can be isolated from the filtrate of the broth by its adsorption on an anion exchange resin column.
- a strongly basic anion exchange resin which is a polystyrene-divinylbenzene polymer carrying quaternary ammonium active groups e.g. Dowex AI 400 (OH ⁇ ), Dowex 1 ⁇ 2 (OH ⁇ ), Dowex 2 ⁇ 4 (OH ⁇ ), Amberlite IRA 900 (OH ⁇ ) resins.
- the product adsorbed on the ion exchange resin can be eluted from the column by aqueous acetic acid or a sodium chloride containing acetone-water mixture, preferably by 1% sodium chloride containing acetone-water (1:1) mixture.
- Pravastatin containing fractions are combined and the acetone being in the eluate is distilled off in vacuum.
- the pH of the concentrate is adjusted with 15% sulphuric acid into the range of 3.5-4.0 and the acidified aqueous solution is extracted by ethyl acetate. From the ethyl acetate extract pravastatin can be extracted by 1/10 and 1/20 volume ratio of 5% sodium hydrogen carbonate or weakly alkaline water (pH 7.5-8.0).
- pravastatin can be recovered in a pure form from the above obtained alkaline aqueous extract by column chromatography on a non-ionic adsorption resin.
- An advantageous method is, that first of all the ethyl acetate dissolved in the aqueous phase is removed by vacuum distillation from the alkaline aqueous extract and then the aqueous extract is loaded on a Diaion HP-20 column.
- Pravastatin adsorbed on the column is purified by elution with aqueous acetone in which the acetone content is gradually increased, then the chromatographic fractions containing pravastatin as a single component are combined and concentrated in vacuum.
- the concentrate is clarified with charcoal and lyophilized, then crystallized from an ethanol-ethyl acetate mixture, affording pravastatin in a quality acceptable for pharmaceutical application.
- pravastatin can be extracted either from the fermentation broth or from the filtrate obtained after the separation of the micelium mass.
- the latter can be removed either by filtration or centrifugation, however, it is advantageous especially in an industrial scale to make a whole broth extraction.
- the pH of either the fermentation broth or the filtrate of the broth is adjusted to 3.5-3.7 with a mineral acid preferably with diluted sulphuric acid.
- the extraction is done with acetic acid ester with a 2-4 carbon atom containing aliphatic alcohol preferably with ethyl acetate or isobutyl acetate.
- the ethyl acetate extract is washed with water and dried with anhydrous sodium sulphate.
- the lactone derivative is prepared from pravastatin.
- the lactone ring closure is carried out in dried ethyl acetate solution at room temperature, under continuous stirring by inducing the lactone formation with catalytic amount of trifluoro-acetic acid.
- the lactone ring closure is checked by thin layer chromatographic analysis (TLC). After finishing the lactone formation the ethyl acetate solution is washed at first with 5% aqueous sodium hydrogen carbonate solution and then with water, and it is dried with anhydrous sodium sulphate and evaporated in vacuum.
- TLC thin layer chromatographic analysis
- Pravastatin is prepared from the pravastatin lactone by hydrolysis at room temperature in acetone with equivalent quantity of sodium hydroxide. When the pravastatin sodium salt formation has been completed, the pravastatin is precipitated with acetone. Then the precipitate is filtered and washed with acetone and n-hexane and dried in vacuum, then crystallized from an ethanol-ethyl acetate mixture.
- pravastatin can be precipitated as a crystalline salt with secondary amines. Further it was found, that for the salt formation several secondary amines containing alkyl-, cycloalkyl-, aralkyl- or aryl-substituents are appropriate.
- non-toxic secondary amines were selected among them, e.g., dioctylamine, dicyclohexylamine, dibenzylamine.
- the isolation of the organic secondary amine salt intermediates, e.g., the dibenzylamine salt was carried out by adding dibenzylamine in 1.5 equivalent quantity related to the pravastatin content of the extract, then the extract is concentrated by vacuum distillation to 5% of its original volume, then another quantity of dibenzylamine is added into the concentrate in 0.2 equivalent ratio.
- the crystalline dibenzylamine salt is precipitated from the concentrate.
- the crystalline crude product is filtered and dried in vacuum, and it is clarified with charcoal in methanol or acetone solution. Then with recrystallization of the clarified product from acetone chromatographically pure pravastatin dibenzylamine salt intermediate can be obtained.
- Pravastatin organic secondary amine salts can be transformed to pravastatin by sodium hydroxide or a sodium alkoxide preferably sodium ethoxide.
- pravastatin via a secondary amine salt intermediate is a simpler procedure than any of the ever known isolation procedures. During the procedure artefacts are not formed, and the separation of pravastatin from the by-products of the bioconversion and from the various metabolic products biosynthesized by the hydroxylating microorganism can be advantageously solved.
- SM soluble starch agar
- IDR-P 3 [NCAIM (P) B 001268] strain and suspended in 5 ml of sterile distilled water. This suspension was then used to inoculate 100 ml of sterile TI inoculum medium in a 500 ml Erlenmeyer flask.
- Agar 15.0 g in 1000 ml of distilled water
- the pH of the medium was adjusted to 7.0 before sterilization and the mixture was sterilized at 121° C. for 25 minutes.
- the pH was adjusted to 7.0 before sterilization and heat treated at 121° C. for 25 minutes.
- the developing culture was shaken on a rotary shaker (250 r.p.m.; and amplitude: 2.5 cm) for 3 days, at 32° C., then 5 ml aliquots from it were used to inoculate 10 Erlenmeyer flasks of 500 ml volume each containing 100 ml of TT medium sterilized at 121° C. for 25 minutes.
- Composition of TT medium Potato starch 30.0 g Soybean meal 30.0 g CaCO 3 5.0 g CoCl 2 ⁇ 6H 2 O 2.0 mg Palm oil 2.0 g in 1000 ml of tap water
- the pH was adjusted to 7.0 before heat sterilization.
- the incubation was carried out at 32° C. for 72 hours then 50 mg of compactin acid sodium salt was added to each flask in distilled water, and the cultivation was carried out for 96 hours.
- the conversion rate of compactin acid sodium salt into pravastatin measured by HPLC was 82%.
- the fermentation broth was centrifuged at 2500 r.p.m. for 20 min. The supernatant of the broth and the mycelial mass were separated, then the latter was resuspended in 250 ml of water and the obtained suspension was stirred for one hour and filtered. The pH of the combined centrifuged broth and the filtrate was adjusted by 15% sulphuric acid to 4.0, then the acidic filtrate was extracted with 3 ⁇ 300 ml of ethyl acetate.
- pravastatin lactone was prepared from pravastatin by adding trifluoroacetic acid in catalytical amount at room temperature under continuous stirring. Formation of pravastatin lactone was controlled by TLC method: adsorbent: Kieselgel 60 F 254 DC (Merck) aluminium foil; developing solvent: acetone-benzene-acetic acid (50:50:1.5) mixture; detection: with phospho-molybdic acid reagent. The R f value of pravastatin lactone was 0.7.
- Pravastatin lactone was eluted from the column with the mixture of 60% ethyl acetate-40% n-hexane. The fractions containing pravastatin lactone were combined and evaporated in vacuum. The residue obtained, which contained 230 mg of pravastatin lactone, was dissolved in 5 ml of acetone and then under stirring 110 mole % of sodium hydroxide was added in 1M ethanolic solution. Stirring of the solution was continued for half an hour at room temperature. Subsequently, the solution was concentrated to 2 ml volume and 4 ml of acetone was added to the concentrate. The mixture was kept at +5° C. overnight.
- Negative FAB mass spectrum (characteristic ions): [M ⁇ H] ⁇ 445, [M ⁇ Na] ⁇ 423, m/z 101 [2-methyl-butyric acid-H] ⁇ .
- the pH of the bioconversion medium was adjusted to 7.0 before sterilization.
- the mixture was sterilized at 121° C. for 25 minutes.
- the united broth, which contained 750 mg of pravastatin according to the HPLC assay was centrifuged at 2500 r.p.m. for 20 min.
- the separated micelium mass was stirred with 250 ml of water for an hour, then filtered.
- the centrifuged broth the filtrate were combined and the pH of the resulting solution was adjusted to a 3.5-4.0 value, with 15% sulphuric acid, then the solution was extracted with 3 ⁇ 300 ml of ethyl acetate.
- 150 mole % of dibenzylamine—calculated for the pravastatin content— was added to the ethyl acetate extract.
- the ethyl acetate extract was evaporated to about 30 ml volume and the suspension was kept overnight at 0-5° C.
- the precipitated pravastatin acid dibenzylamine salt was filtered and washed on the filter with cooled ethyl acetate and n-hexane, finally dried in vacuum.
- the 1.1 g of crude pravastatin acid dibenzylamine salt was dissolved in 33 ml of acetone at 62-66° C. temperature, and the solution was clarified with 0.1 g of charcoal for half an hour. Then the charcoal was removed by filtration from the solution. Crystals precipitated from the clarified solution were dissolved again at the above temperature, then the solution was kept at +5° C. overnight.
- the precipitate was filtered, washed with cooled acetone and n-hexane and dried in vacuum.
- Pravastatin acid dibenzylamine salt obtained (0.7 g) was suspended in 10 ml of ethanol, then 110 mole % of sodium hydroxide was added to the solution by feeding 1M aqueous solution. Stirring of the alkaline solution was continued for half an hour at room temperature. After the completion of the sodium salt formation 30 ml of water was added and the pH of the solution was neutralized, then ethanol was distilled off in vacuum.
- the aqueous concentrate was chromatographed on a column filled with 50 ml of Dialon HP 20 resin (diameter of the column: 1.5 cm, height of the resin bed: 28 cm).
- the column was eluted with acetone-deionized water mixtures, where the concentration of the acetone was increased in 5% steps.
- Pravastatin could be eluted from the column by a 15% acetone containing acetone-deionized water mixture.
- Fractions were analysed by TLC method given in the Example 1.
- the R f value of pravastatin was 0.5.
- Fractions containing pravastatin were combined and the acetone content was evaporated in vacuum. By the lyophilization of the aqueous residue 390 mg of chromatographically pure pravastatin was obtained.
- the conversion rate of compactin acid sodium salt into pravastatin was about 90% in the bioconversion process.
- Composition of TT/2 bioconversion medium Glucose 75.0 g Soluble starch 50.0 g Soybean meal 50.0 g Yeast extract 50.0 g Pepton 5.0 g NaNO 3 20.0 g CaCO 3 25.0 g in 4500 ml of tap water
- TT/1 fermentation medium 4.5 litres of the TT/1 fermentation medium, in a laboratory fermentor were sterilized at 121° C. for 45 minutes and inoculated with 500 ml of the inoculum shake culture prepared as described In Example 1, then incubated at 28° C., aerated with 200 l sterile air/h and stirred with a flat blade stirrer at 400 r.p.m.
- Composition of TT/1 bioconversion medium Glucose 125.0 g Potato starch 25.0 g Soybean meal 50.0 g Yeast extract (Gistex) 50.0 g Pepton 50.0 g CoCl 2 ⁇ 6H 2 O 10.0 mg Sunflower oil 10.0 g in 4500 ml of tap water
- the pH of the bioconversion medium was adjusted to 7.0 before sterilization.
- a spore suspension was prepared with 5 ml of sterile distilled water from the surface of a 10 days old, soluble starch agar slant culture, as described in Example 1, of Micromonospora echinospora ssp. echinospora IDR-P 5 [NCAIM (P) B 001272] strain—being able for the 6 ⁇ -hydroxylation of compactin acid sodium salt—and the obtained spore suspension was used to inoculate 100 ml of inoculum medium TI sterilized in a 500 ml Erienmeyer flask. Composition of the medium TI was also described in Example 1.
- the inoculated medium was shaken on a rotary shaker (250 r.p.m., 2.5 cm amplitude) for 3 days at 28° C., then 5 ml aliquots of the developed culture were transferred into 100-100 ml of bioconversion medium TT/1 sterilized in 500 ml Erlenmeyer flasks for 25 min at 121° C. Composition of the medium TT/1 is described In Example 4. Flasks were shaken on a rotary shaker (250 r.p.m. 2.5 cm amplitude) for 3 days at 25° C., then 10-10 mg of compactin substrate (compactin acid sodium salt) was added in sterile filtered aqueous solution into the cultures, then the fermentation was continued for 168 hours.
- compactin substrate compactin acid sodium salt
- the pravastatin content of the fermentation broth was determined by an HPLC method. At this time the average pravastatin concentration was 40 ⁇ g/ml.
- the fermentation, substrate feeding and bioconversion were carried out with strain IDR-P 6 , [NCAIM (P) B 001273] of Micromonospora megalomicea ssp. nigra as it was written in Example 5.
- the pravastatin content of the fermentation broth was determined by an HPLC method. At the end of the bioconversion the pravastatin content of the broth was 50 ⁇ g/ml.
- the pH of the bioconversion medium was adjusted to 7.0 before sterilization.
- Flasks were shaken on a rotary shaker (250 r.p.m., 2.5 cm amplitude) for 3 days.
- the substrate feeding, the bioconversion and determination of the pravastatin content were carried out as described in Example 5.
- the pravastatin content of the fermentation broth was 40 ⁇ g/ml.
Abstract
The present invention relates to a new microbial process for the preparation of compound of formula (I) from a compound of general formula (II) wherein R stands for an alkali metal or ammonium ion, by the submerged culture of a strain which is able to 6β-hydroxylate the compound of formula (II) in aerobic fermentation and by the separation and purification of the product of formula (I) formed in the course of the biocoversion. The latter comprises the cultivation of a Micromonospora strain which is able to 6β-hydroxylate a compound of general formula (II)—wherein R is as defined above—at 25-32° C. on a nutrient medium containing available carbon—and nitrogen sources and mineral salts, thereafter feeding the substrate to be transformed into the developing culture, then hydroxilating the substrate until finishing of the bioconversion, then separating the compound of formula (I) from the culture broth and, if desired, purifying the same.
Description
- The present invention relates to a new microbial process for the preparation of pravastatin.
- More particularly, this invention relates to a microbial process for the preparation of pravastatin of formula (I)
from a compound of the general formula (II)
wherein R stands for an alkali metal or ammonium ion, with a microorganism, wherein said microorganism is a prokaryote from genus Micromonospora, which is able to hydroxylate a compound of the general formula (II) at the 6βposition. - The hypercholesterolaemia has been recognized as a major risk factor for atherosclerotic disease, specifically for coronary heart disease. During the past two decades 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase EC. 1.1.1.34) as the major rate-limiting enzyme in the cholesterol biosynthesis, has been extensively studied. Mevinolin and related compounds biosynthesised by selected strains of different fungal species were found to be competitive inhibitors of this enzyme [Endo, A. et al., J. Antibiotics 29, 1346-1348 (1976); Endo, A. et al., FEBS Lett. 72, 323-326 (1976): Kuo, C. H. et al., J. Org. Chem. 48, 1991-1998 (1983)].
- Pravastatin is also a member of the family of HMG-CoA reductase inhibitors. At first, pravastatin was found as a minor urinary metabolite of compactin in dog (Tanaka, M. et al., unpublished) in the course of metabolic studies of compactin [Arai, M. et al. Sankyo Kenkyusho Nempo, 40, 1-38 (1988)].
- The main characteristic property of pravastatin as the hydroxylated product of compactin is its tissue selectivity. This drug strongly inhibits sterol synthesis in liver and in intestine, but weakly in other organs. It is advantageous that pravastatin possesses lower toxicity than the other HMG-CoA reductase inhibitors.
- It has been reported that microbial hydroxylation of compactin can be accomplished in various extent by several strains of species belonging to many different genera of fungi, and by strains of actinomycete species belonging to the genera Nocardia, Actinomadura and Streptomyces, among others Streptomyces roseochromogenes and Streptomyces carbophilus (U.S. Pat. No. 5,179,013, U.S. Pat. No. 4,448,979, U.S. Pat. No. 4,346,227, U.S. Pat. No. 4,537,859, Japanese Patent No. 58,010,572).
- A problem with using fungi for the production of pravastatin from compactin is that these organisms generally do not tolerate higher concentrations of compactin in liquid culture media, presumably due to its antifungal activity [Serizawa, N. et al., J. Antibiotics 36, 887-891 (1983)]. In Streptomyces carbophilus the cytochrome P450 system has been shown to be required for the hydroxylation of compactin to pravastatin [Matsuoka, T. et al., Eur. J. Biochem. 184, 707-713 (1989)]. Difficulty of genetic improvement of the ability of hydroxylation with the use of such an enzyme is that it is a complex of proteins rather than a single protein.
- Our investigation were focused on finding an actinomycete strain which would produce pravastatin from salts of acidic form of compactin with higher yield and by applying higher substrate concentration in the bioconversion than those known from former patent specifications.
- During the screening, covering about 6000 actinomycetes, mostly our own isolates, but also authentic strains from international strain collections, five Streptomyces and five Micromonospora were selected for further studies, because they proved to be able to hydroxylate the sodium salt of the acidic form of compactin into pravastatin. These ten actinomycete strains, from which eight strains have been taxonomically identified at species level in our laboratory, were the following:
- Streptomyces violaceus (according to Kämpfer et al. 1991), strain No. 1/43.
- Streptomyces rochel (Berger et al., 1949; Waksman and Lechevalier, 1953), strain No. 1/41.
- Streptomyces resistomycificus (Lindenbein, 1952), strain No. 1/44.
- Streptomyces sp., strain No. 1/28.
- Streptomyces lanatus, (Frommer, 1959), strain No. 1/16.
- Micromonospora sp., strain No. IDR-P3.
- Micromonospora purpurea (Luedemann and Brodsky, 1964), strain No. IDR-P4.
- Micromonospora echinospora (Luedemann and Brodsky, 1964), strain No. IDR-P5.
- Micromonospora megalomicea (Weinstein et al, 1969), strain No. IDR-P6.
- Micromonospora rosaria (Horan and Brodsky, 1986), strain No. IDR-P7.
- Since, up to now, there are no data in the literature on the ability of Micromonospora to convert salts of the acidic form of compactin into pravastatin, we have thoroughly studied not only this particular enzymatic ability, but also the taxonomic position of these above listed strains of Micromonospora.
- Taxonomic Position of Strains IDR-P3, —P4, —P5, —P6 and —P7 at Generic Level
- All of these strains produced well developed mycelia, composed of branched hyphae of about 0.4-0.7 μm in diameter. Aerial mycelium is absent or occurs only in traces. Nonmotile spores are borne on sporophores singly. Hyphae of the substrate mycelium are Gram-positive and not acid-fast. Stains Nos. IDR P3-P7 are aerobic, chemo-organotrophic and sensitive to pH below 6.0. Walls contain meso-diaminopimelic acid. The above listed diagnostic properties—as key characters—clearly demonstrate. That these monosporic actinomycete strains are typical members of the genus Micromonospora.
- Taxonomic description of Micromonospora sp., strain No. IDR-P3
- Micromorphological properties: Substrate mycelium is composed of well developed, more curved than straight, monopodially branching filaments. Spores on the sporophores are single, spherical approximately 1.8 μm in diameter and dispersing more or less evenly on hyphal filaments. Spores are either sessile or on the end of short sporophores. In broth cultures spores were not observed on the hyphae presumably because the release of mature spores is very quick.
- Cultural-Macromorphological Properties:
-
- Czapek-sucrose agar: Medium growth, the colonies have reddish colour covered by point-like black sporulating areas.
- Glucose-asparagine agar: The growth was recorded as point like and elevated, reddish-brown or black colonies. Reddish diffusible pigments.
- Nutrient agar: Fair growth, elevated, reddish-brown or black colonies. Reddish-brown exopigment in the medium.
- Yeast extract-malt extract agar (ISP Med. 2): Well developed, elevated and wrinkled, brown colonies, covered partly with black sporulating areas or with “pseudo-aerial mycelium” (this is appearing as a restricted whitish or greyish bloom). Brownish or brownish-red soluble pigment.
- Inorganic salts-starch agar (ISP Med. 4): Medium growth of reddish-brown elevated and wrinkled colonies. Light reddish soluble pigment.
- Glycerol-asparagine agar (ISP Med. 5): Growth only in traces, off-white or light orange coloured, flat colonies, light rose soluble pigment.
- Carbon source utilization: Good growth on and positive utilization of L-arabinose, D-galactose, D-fructose, D-glucose, D-xylose, lactose, meliblose, sucrose, D-mannitol, dulcitol, glycerol and inositol. Growth with L-rhamnose, D-raffinose and inulin was slightly better than on the negative control medium. Nitrogen source utilization: Good growth with yeast extract and NZ-Amine, no or weak utilization of NaNO3.
- Other physiological-biochemical properties: Cellulose and starch are hydrolyzed, milk is digested strongly. Nitrate reduction test is negative. No growth on potato slices without calcium carbonate (pH 5.8-6.0). No melanoid pigment production.
- This strain No. IDR-P3 of Micomonospora sp. was isolated from a mud sample of Lake Balaton (Hungary).
- Systematic position: Further comparative systematic studies would be necessary to clarify the exact taxonomic position of this strain among the species of the genus Micromonospora. On the basis of certain properties it seems to be not impossible, that strain IDR-P3 represents a new species within the genus Micromonospora.
- Differential-Diagnostic Description and Identification of Micromonospora Strains IDR-P4, —P5, —P6 and P7
- Strain IDR-P4
- On the above listed diagnostic media, generally, good growth, orange to orange red, red, sometimes yellowish or rose coloured colonies. Soluble pigments and aerial mycelium are not produced. The number of solitary spores is relatively low. They occur on the sporophores terminally. Substrate mycelium is composed of well branching hyphae. Aerial mycelium absent. No growth on D-melibiose, raffinose, mannitol, glycerol, lactose, L-rhamnose but good growth on D-arabinose, glucose, D-xylose and weak growth on D-galactose and D-fructose. On the basis of these conventional diagnostic properties we have identified this strain as a member of species Micromonospora purpurea (Luedemann and Brodsky, 1964).
- Strain IDR-P5
- This strain produces mostly solitary sporophores and sphaerical dark brown to black spores (0.8-1.5 μm in diameter) which adhere firmly to the sporophores until maturation. According to our electronmicroscopic observations, on the surface of these spores warty structures or outgrowths (“blunt spines” according to the Vol. 4 of Bergey's Manual of Syst. Bact 1989, pages 2448) can be observed, which is very characteristic of the spores of Micromonospora echinosora. Otherwise, the cultural-morphological and physiological diagnostic properties of this strain are also very similar to those of the M. echinospora. The colour of the well developed colonies on the standard diagnostic media is orange-brown or dark purple. The sporulating layer is black or purplish black, waxy. Aerial mycelium absent. Melanin pigment not produced. Milk digested. Good growth on D-xylose, D-arabinose, D-glucose, and sucrose, but no growth with L-rhamnose, raffinose, D-galactose, D-fructose, D-meliblose and glycerol. We consider this strain as a typical member of Micromonospora echinospora.
- Strain IDR-P6
- On the majority of diagnostic media moderate to weak growth. The orange or orange red colonies consist of long branched filaments (appr. 0.6 μm in diameter) and a limited number of solitary, sphaerical, dark coloured spores (0.6-1.0 μm in diameter). Does not produce aerial mycelium. In certain media weak reddish or rose coloured soluble pigments are formed. On tyrosine agar melanold pigments were not produced. On a basal medium the following carbon sources have been utilized by this strain: D-xylose and D-fructose; only weakly: D-melibiose, mannitol and galactose, but no or sporadic growth was observed with glycerol, L-rhamnose, lactose and raffinose (see also Kawamoto, I. et al.: Agric. Biol. Chem., 47, 203-215, 1983). Strain No. IDR-P6 shows a considerable similarity to the species Micromonospora megalomicea, (Weinstein, 1972) and we consider it as a member of this species.
- Strain IDR-P7
- Good to moderate growth on Bennett agar, Czapek sucrose agar, glucose-asparagine agar, nutrient agar, oatmeal agar, potato-dextrose agar, etc. The colour of the vegetative mycelial pigments ranges from reddish-brown to purplish-brown. On certain media wine red diffusible pigments are formed. On the surface of the colonies black spots are frequently produced. Vegetative hyphae (average diameter: 0.5 μm) are intensively branched. Spores (1.4-1.7 μm in diameter) are borne singly, sessile or on short sporophores and occur along the length of the hyphae. Growth and sporulaton are of open web type of Luedemann. The following compounds are utilized by this strain as only source of carbon in medium: D-glucose, lactose, D-mannitol. L-rhamnose, sucrose and D-xylose. Dulcitol, glycerol, D-melibiose and D-raffinose are not utilized. We have identified strain No. IDR-P7 as a typical member of Micromonospora rosaria (Horan and Brodsky, 1986).
- The above presented Micromonospora strains were deposited at the National Collection of Agricultural and Industrial Microorganisms (NCAIM), Budapest, Hungary, under the below given number-designations:
Micromonospora sp. IDR-P3 NCAIM (P) B 001268 Micromonospora purpurea IDR-P4 NCAIM (P) B 001271 Micromonospora echinospora ssp. echinospora NCAIM (P) B 001272 IDR-P5. Micromonospora megalomicea ssp. nigra NCAIM (P) B 001273 IDR-P6. Micromonospora rosaria IDR-P7. NCAIM (P) B 001274
Based on the above the invention relates to a new microbial process for the preparation of pravastatin of formula (I)
from a compound of general formula (II),
wherein R stands for an alkali metal or ammonium ion, by the submerged cultivation of a strain which is able to 6β-hydroxylate a compound of formula (II) in aerobic fermentation and by the separation and purification of the compound of formula (I) formed in the course of the bioconversion comprising the steps of - a) cultivating a strain of a species belonging to the genus Micromonospora which is able to 6β-hydroxylate a compound of formula (II)— wherein R is as defined above—on a nutrient medium containing assimilable carbon—and nitrogen sources and mineral salts at 25-32° C., thereafter
- b) feeding the substrate to be transformed into the developed culture, then
- c) hydroxylating the substrate until the end of bioconversion, then
- d) separating the compound of formula (I) from the culture broth and, if desired, purifying the same.
- The scope of the invention extends to the wild strains and any mutants of species belonging to the genus Micromonospora which are able to hydroxylate the sodium salt of the acid form of compactin to pravastatin.
- According to a preferred embodiment of the present invention pravastatin is produced with a Micromonospora strain selected from the group consisting of Micromonospora sp. IDR-P3 [NCAIM (P) B 001268], Micromonospora purpurea IDR-P4 [NCAIM (P) B 001271], Micromonospora echinospora IDR-P5 [NCAIM (P) B 001272], Micromonospora megalomicea IDR-P6 [NCAIM (P) B 001273] and Micromonospora rosaria IDR-P7 [NCAIM (P) B 001274].
- According to the most preferred embodiment of the invention pravastatin is produced with Micromonospora sp. strain IDR-P3 [NCAIM (P) B 001268].
- The present invention can be carried out by in situ fermentation method, that is when, hydroxylation is accomplished with the participation of an actively growing Micromonospora culture.
- The hydroxylation may be conducted by employing agitation as shake-flask culture or aeration and agitation in fermentors, when the compound of the formula (II) is added to the growing cultures. In such cases an anti-foaming agent may be employed. The adequate density of culture of this strain could be achieved by the use of an appropriate medium containing available carbon and nitrogen sources, inorganic salts as well as trace elements.
- E.g. glucose, glycerol, dextrin, starch, rhamnose, xylose, sucrose and soluble starch proved to be assimilable carbon sources while soybean meal, corn steep liquor, peptone, yeast extract, meat extract, ammonium citrate and ammonium sulfate as good nitrogen sources. Inorganic salts such as calcium carbonate, sodium phosphates, potassium phosphates etc., may be added to the culture medium. Preferred media for the growth of this selected strain are those described in the examples.
- The bioconversion of compactin to pravastatin can be done by different fermentation techniques, e.g., batch culture, fed-batch culture. Preferably, an agitated liquid submerged culture is used. The preferred temperature is about 25° C. to 37° C., most preferably about 25° C. to 32° C.
- The preferred pH is about 6.0 to 9.0, most preferably about 7.0 to 8.5. The preferred shaking condition is about 200 rpm to 400 rpm, most preferably about 250 rpm.
- The invention provides a method for converting compactin acid sodium salt to pravastatin. Compactin acid sodium salt can be used in this invention at any concentration which will result in production of pravastatin. Preferably, the compactin concentration is between 0.1 and 10 g/liter, more preferably is between about 0.3 and 3.0 g/liter.
- The invention is meant to cover any percentage of conversion of compactin to pravastatin by the strains of Micromonospora spp., at least 30% and most preferably at least about 90%.
- In the course of the fermentation the composition of the culture broth is controlled by a high performance liquid chromatographic (HPLC) method. According to the HPLC method the sample of the broth is diluted twofold with methonol, centrifuged and the supernatant is used for the analysis. Parameters of the HPLC system used for the analysis are: Waters analytical HPLC equipment; column packing: Waters Novapack C18 5 μm; measurement at 237 nm; injection volume 10 μl; flow rate 0.6-0.9 ml/min linear gradient; gradient elution is used, eluents: solvent A=acetonitrile−0.1 M NaH2PO4 in water (25:75), solvent B=acetonitrile−water (pH 2 with H3PO4) (70:30).
- Parameters of Gradient Elution:
Flow rate Time (min) (ml/min) Eluent A (%) Eluent B (%) 0 0.6 100 0 2 0.7 100 0 12 0.9 0 100 21 0.9 0 100 22 0.9 100 0 27 0.7 100 0 - Retention times: pravastatin (Na salt) 10.6 min; compactin (acid Na salt) 19.5 min; pravastatin (lactone form) 17.3 min, compactin (lactone form) 23.5 min.
- Any known method can be used for the isolation of pravastatin, e.g., extraction-reextraction, anion exchange chromatography, precipitation.
- For the recovery of the product from the broth it is advantageous to take into consideration the fact, that during the bioconversion pravastatin is formed in its acidic form, thus it can be isolated from the filtrate of the broth by its adsorption on an anion exchange resin column. For the isolation of the product it is advantageous to use a strongly basic anion exchange resin which is a polystyrene-divinylbenzene polymer carrying quaternary ammonium active groups e.g. Dowex AI 400 (OH−), Dowex 1×2 (OH−), Dowex 2×4 (OH−), Amberlite IRA 900 (OH−) resins. The product adsorbed on the ion exchange resin can be eluted from the column by aqueous acetic acid or a sodium chloride containing acetone-water mixture, preferably by 1% sodium chloride containing acetone-water (1:1) mixture. Pravastatin containing fractions are combined and the acetone being in the eluate is distilled off in vacuum. The pH of the concentrate is adjusted with 15% sulphuric acid into the range of 3.5-4.0 and the acidified aqueous solution is extracted by ethyl acetate. From the ethyl acetate extract pravastatin can be extracted by 1/10 and 1/20 volume ratio of 5% sodium hydrogen carbonate or weakly alkaline water (pH 7.5-8.0). It was experienced, that pravastatin can be recovered in a pure form from the above obtained alkaline aqueous extract by column chromatography on a non-ionic adsorption resin. An advantageous method is, that first of all the ethyl acetate dissolved in the aqueous phase is removed by vacuum distillation from the alkaline aqueous extract and then the aqueous extract is loaded on a Diaion HP-20 column.
- Pravastatin adsorbed on the column is purified by elution with aqueous acetone in which the acetone content is gradually increased, then the chromatographic fractions containing pravastatin as a single component are combined and concentrated in vacuum. The concentrate is clarified with charcoal and lyophilized, then crystallized from an ethanol-ethyl acetate mixture, affording pravastatin in a quality acceptable for pharmaceutical application.
- After finishing the bioconversion pravastatin can be extracted either from the fermentation broth or from the filtrate obtained after the separation of the micelium mass. The latter can be removed either by filtration or centrifugation, however, it is advantageous especially in an industrial scale to make a whole broth extraction. Before extraction the pH of either the fermentation broth or the filtrate of the broth is adjusted to 3.5-3.7 with a mineral acid preferably with diluted sulphuric acid. The extraction is done with acetic acid ester with a 2-4 carbon atom containing aliphatic alcohol preferably with ethyl acetate or isobutyl acetate. The ethyl acetate extract is washed with water and dried with anhydrous sodium sulphate. Then the lactone derivative is prepared from pravastatin. The lactone ring closure is carried out in dried ethyl acetate solution at room temperature, under continuous stirring by inducing the lactone formation with catalytic amount of trifluoro-acetic acid. The lactone ring closure is checked by thin layer chromatographic analysis (TLC). After finishing the lactone formation the ethyl acetate solution is washed at first with 5% aqueous sodium hydrogen carbonate solution and then with water, and it is dried with anhydrous sodium sulphate and evaporated in vacuum. The residue is purified with silica gel column chromatography used as the eluent mixtures of ethyl acetate—n-hexane with gradually increasing ethyl acetate content. Pravastatin is prepared from the pravastatin lactone by hydrolysis at room temperature in acetone with equivalent quantity of sodium hydroxide. When the pravastatin sodium salt formation has been completed, the pravastatin is precipitated with acetone. Then the precipitate is filtered and washed with acetone and n-hexane and dried in vacuum, then crystallized from an ethanol-ethyl acetate mixture.
- It was found, that the chromatography on Sephadex LH-20 gel is advantageously applicable for purifying pravastatin. By application of this method pravastatin exceeding the purity of 99.5% (measured by HPLC) can be produced.
- In the course of our experiments the following invention has been recognized: from the organic solvent extract, preferably from the ethyl acetate or isobutyl acetate extract of the broth or the broth filtrate of Micromonospora sp. IDR-P3 strain which is able to 6β-hydroxylate a compound of general formula (II), pravastatin can be precipitated as a crystalline salt with secondary amines. Further it was found, that for the salt formation several secondary amines containing alkyl-, cycloalkyl-, aralkyl- or aryl-substituents are appropriate. Expediently non-toxic secondary amines were selected among them, e.g., dioctylamine, dicyclohexylamine, dibenzylamine. The isolation of the organic secondary amine salt intermediates, e.g., the dibenzylamine salt was carried out by adding dibenzylamine in 1.5 equivalent quantity related to the pravastatin content of the extract, then the extract is concentrated by vacuum distillation to 5% of its original volume, then another quantity of dibenzylamine is added into the concentrate in 0.2 equivalent ratio. The crystalline dibenzylamine salt is precipitated from the concentrate. The crystalline crude product is filtered and dried in vacuum, and it is clarified with charcoal in methanol or acetone solution. Then with recrystallization of the clarified product from acetone chromatographically pure pravastatin dibenzylamine salt intermediate can be obtained.
- Pravastatin organic secondary amine salts can be transformed to pravastatin by sodium hydroxide or a sodium alkoxide preferably sodium ethoxide.
- The isolation of pravastatin via a secondary amine salt intermediate is a simpler procedure than any of the ever known isolation procedures. During the procedure artefacts are not formed, and the separation of pravastatin from the by-products of the bioconversion and from the various metabolic products biosynthesized by the hydroxylating microorganism can be advantageously solved.
- The process according to the invention is presented by the following examples.
- Spores were obtained from the surface of a 7-10 day old, soluble starch agar (SM) slant culture of Micromonospora sp. IDR-P3 [NCAIM (P) B 001268] strain and suspended in 5 ml of sterile distilled water. This suspension was then used to inoculate 100 ml of sterile TI inoculum medium in a 500 ml Erlenmeyer flask.
Composition of SM medium Soluble starch 10.0 g Na2HPO4 1.15 g KH2PO4 0.25 g KCl 0.2 g MgSO4 × 7H2O 0.2 g Agar 15.0 g in 1000 ml of distilled water - The pH of the medium was adjusted to 7.0 before sterilization and the mixture was sterilized at 121° C. for 25 minutes.
Composition of TI medium Soluble starch 20.0 g Yeast extract 10.0 g in 1000 ml of tap water - The pH was adjusted to 7.0 before sterilization and heat treated at 121° C. for 25 minutes.
- The developing culture was shaken on a rotary shaker (250 r.p.m.; and amplitude: 2.5 cm) for 3 days, at 32° C., then 5 ml aliquots from it were used to inoculate 10 Erlenmeyer flasks of 500 ml volume each containing 100 ml of TT medium sterilized at 121° C. for 25 minutes.
Composition of TT medium Potato starch 30.0 g Soybean meal 30.0 g CaCO3 5.0 g CoCl2 × 6H2O 2.0 mg Palm oil 2.0 g in 1000 ml of tap water - The pH was adjusted to 7.0 before heat sterilization.
- The incubation was carried out at 32° C. for 72 hours then 50 mg of compactin acid sodium salt was added to each flask in distilled water, and the cultivation was carried out for 96 hours. The conversion rate of compactin acid sodium salt into pravastatin measured by HPLC was 82%.
- After finishing the fermentation the cultures were united, and from the obtained collective fermentation broth, which contained 410 mg of pravastatin, the isolation of the latter was carried out as follows: The fermentation broth was centrifuged at 2500 r.p.m. for 20 min. The supernatant of the broth and the mycelial mass were separated, then the latter was resuspended in 250 ml of water and the obtained suspension was stirred for one hour and filtered. The pH of the combined centrifuged broth and the filtrate was adjusted by 15% sulphuric acid to 4.0, then the acidic filtrate was extracted with 3×300 ml of ethyl acetate. The combined ethyl acetate extracts were washed with 300 ml of water, dried with anhydrous sodium sulphate and concentrated in vacuum to 100 ml volume. Then pravastatin lactone was prepared from pravastatin by adding trifluoroacetic acid in catalytical amount at room temperature under continuous stirring. Formation of pravastatin lactone was controlled by TLC method: adsorbent: Kieselgel 60 F254 DC (Merck) aluminium foil; developing solvent: acetone-benzene-acetic acid (50:50:1.5) mixture; detection: with phospho-molybdic acid reagent. The Rf value of pravastatin lactone was 0.7. After the completion of the lactone formation the ethyl acetate was washed with 2×20 ml of 5% aqueous sodium hydrogen carbonate then washed with 20 ml of water, dried with anhydrous sodium sulphate and evaporated in vacuum. 0.5 g of evaporation residue was obtained, which was chromatographed on 10 g of Kieselgel 60 adsorbent containing column (diameter of the column: 1.2 cm, height of the adsorbent bed: 17 cm). For elution ethyl acetate-n-hexane mixtures were used in which the ethyl acetate content was gradually increased. Pravastatin lactone was eluted from the column with the mixture of 60% ethyl acetate-40% n-hexane. The fractions containing pravastatin lactone were combined and evaporated in vacuum. The residue obtained, which contained 230 mg of pravastatin lactone, was dissolved in 5 ml of acetone and then under stirring 110 mole % of sodium hydroxide was added in 1M ethanolic solution. Stirring of the solution was continued for half an hour at room temperature. Subsequently, the solution was concentrated to 2 ml volume and 4 ml of acetone was added to the concentrate. The mixture was kept at +5° C. overnight. The precipitate was filtered, washed with 2 ml of acetone and then with 2 ml of n-hexane and dried in vacuum at room temperature. The resulting crude pravastatin was dissolved in ethanol, clarified by charcoal, then crystallized from ethanol-ethyl acetate mixture. In this way 170 mg of pravastatin was obtained.
- Melting point 170-173° C. (decomp.)
- [α]D 2=+156° (c=0,5, in water).
- Ultraviolet absorption spectrum (20 μg/ml, in methanol): λmax=231, 237, 245 nm (log ε=4.263; 4.311; 4.136).
- Infrared absorption spectrum (KBr): vOH 3415, vCH 2965, vC=0 1730, vCOO-1575 cm−1.
- 1H-NMR spectrum (D2O, δ, ppm): 0.86, d, 3H (2-CH3); 5.92, dd, J=10.0 and 5.4 Hz, 1H (3-H); 5.99, d, J=10.0 Hz, 1H (4-H); 5.52, br, 1H (5-H); 4.24, m, 1H (6-H); 5.34, br, 1H (8-H); 4.06, m, 1H (β-H), 3.65, m, 1H (δ-H); 1.05, d, 3H (2′-CH3); 0.82, t, 3H (4′-H3).
- 13C-NMR spectrum (D2O, δ, ppm): 15.3, q (2-CH3); 139.5, d (C-3); 129.5, d (C-4); 138.1, s (C-4a); 127.7, d (C-5); 66.6, d (C-6); 70.1, d (C-8); 182.6, s (COO−); 72.6, d (C-β); 73.0, d (C-δ); 182.0, s (C-1′); 18.8, q (2′-CH3); 13.7, q (C-4′).
- Positive FAB mass spectrum (characteristic ions): [M+Na]+469; [M+H]+447.
- Negative FAB mass spectrum (characteristic ions): [M−H]−445, [M−Na]−423, m/z 101 [2-methyl-butyric acid-H]−.
- 10 Erlenmeyer flasks of 500 ml volume each containing 100 ml of MT1 bioconversion medium were inoculated with inoculum culture prepared as described in Example 1, then incubated at 28° C. for 96 hours and 50 mg of compactin acid sodium salt was added to each flask in distilled water, then the hydroxylation was carried out for 72 hours when another 50-50 mg of substrate was added to the cultures in distilled water and the fermentation was continued for 72 hours.
Composition of MT1 bioconversion medium Potato starch 10.0 g Dextrose 20.0 g Soybean meal 10.0 g Yeast extract 10.0 g CaCO3 5.0 g Sunflower oil 2.0 g in 1000 ml of tap water - The pH of the bioconversion medium was adjusted to 7.0 before sterilization. The mixture was sterilized at 121° C. for 25 minutes.
- After finishing the bioconversion period the cultures were united and the pravastatin was isolated from the collective broth according to the following procedure:
- The united broth, which contained 750 mg of pravastatin according to the HPLC assay was centrifuged at 2500 r.p.m. for 20 min. The separated micelium mass was stirred with 250 ml of water for an hour, then filtered. The centrifuged broth the filtrate were combined and the pH of the resulting solution was adjusted to a 3.5-4.0 value, with 15% sulphuric acid, then the solution was extracted with 3×300 ml of ethyl acetate. Then 150 mole % of dibenzylamine—calculated for the pravastatin content—was added to the ethyl acetate extract. The ethyl acetate extract was evaporated to about 30 ml volume and the suspension was kept overnight at 0-5° C. The precipitated pravastatin acid dibenzylamine salt was filtered and washed on the filter with cooled ethyl acetate and n-hexane, finally dried in vacuum. The 1.1 g of crude pravastatin acid dibenzylamine salt was dissolved in 33 ml of acetone at 62-66° C. temperature, and the solution was clarified with 0.1 g of charcoal for half an hour. Then the charcoal was removed by filtration from the solution. Crystals precipitated from the clarified solution were dissolved again at the above temperature, then the solution was kept at +5° C. overnight. The precipitate was filtered, washed with cooled acetone and n-hexane and dried in vacuum. Pravastatin acid dibenzylamine salt obtained (0.7 g) was suspended in 10 ml of ethanol, then 110 mole % of sodium hydroxide was added to the solution by feeding 1M aqueous solution. Stirring of the alkaline solution was continued for half an hour at room temperature. After the completion of the sodium salt formation 30 ml of water was added and the pH of the solution was neutralized, then ethanol was distilled off in vacuum. The aqueous concentrate was chromatographed on a column filled with 50 ml of Dialon HP 20 resin (diameter of the column: 1.5 cm, height of the resin bed: 28 cm). The column was eluted with acetone-deionized water mixtures, where the concentration of the acetone was increased in 5% steps. Pravastatin could be eluted from the column by a 15% acetone containing acetone-deionized water mixture. Fractions were analysed by TLC method given in the Example 1. The Rf value of pravastatin was 0.5. Fractions containing pravastatin were combined and the acetone content was evaporated in vacuum. By the lyophilization of the aqueous residue 390 mg of chromatographically pure pravastatin was obtained.
- 4.5 litres of TT/2 medium, in a laboratory fermentor, were sterilized at 121° C. for 45 minutes and inoculated with 500 ml of inoculum shake culture prepared as described in Example 1, then incubated at 32° C., aerated with 250 l of sterile air/h and stirred with a flat blade stirrer at 300 r.p.m. The incubation was continued for 72 hours and 2.5 g of compactin acid sodium salt was added to the culture. After 48th hour of the bioconversion period the compactin substrate was completely consumed from the fermentation broth, then an additional 2.5 g of compactin acid sodium salt was added again into the culture. The second dose of compactin was consumed within 24 hours. The conversion rate of compactin acid sodium salt into pravastatin was about 90% in the bioconversion process.
Composition of TT/2 bioconversion medium Glucose 75.0 g Soluble starch 50.0 g Soybean meal 50.0 g Yeast extract 50.0 g Pepton 5.0 g NaNO3 20.0 g CaCO3 25.0 g in 4500 ml of tap water - 4.5 litres of the TT/1 fermentation medium, in a laboratory fermentor were sterilized at 121° C. for 45 minutes and inoculated with 500 ml of the inoculum shake culture prepared as described In Example 1, then incubated at 28° C., aerated with 200 l sterile air/h and stirred with a flat blade stirrer at 400 r.p.m.
Composition of TT/1 bioconversion medium Glucose 125.0 g Potato starch 25.0 g Soybean meal 50.0 g Yeast extract (Gistex) 50.0 g Pepton 50.0 g CoCl2 × 6H2O 10.0 mg Sunflower oil 10.0 g in 4500 ml of tap water - The pH of the bioconversion medium was adjusted to 7.0 before sterilization.
- Cultivation was continued at 28° C. for 96 hours. At this time 2.5 g of compactin acid sodium salt was added in sterile filtered aqueous solution to the culture. By the 5th day of fermentation the compactin acid sodium salt was completely consumed from the fermentation broth. Then the substrate feeding was repeated daily for further 3 days in 2.5 g/day portions. The compactin acid sodium salt substrate was gradually consumed during the four days and converted completely to pravastatin. According to the results of HPLC measurements at the end of the fermentation period from 10 g of compactin substrate 9 g of pravastatin has been produced.
- After finishing the bioconversion the pravastatin formed in the concentration of 1800 μg/ml was isolated as follows:
- 5 litres of culture broth were centrifuged at 2500 r.p.m. for 20 min. Then 2 litres of water were added to the separated mycelial mass and the suspension was stirred for one hour and filtered. These two filtrates were united and passed through with a flow rate of 500 ml/hour on a column containing 300 g (540 ml) of Dowex AI 400 (OH−) resin (diameter of the column: 4 cm, height of the resin bed: 43 cm), then the resin bed was washed with 1 litre of deionized water. Thereafter the column was eluted with 1 litre of acetone-water (1:1) mixture containing 10 g of sodium chloride by collecting 50 ml fractions. The fractions were analysed by the TLC method given in the Example 1. Fractions containing the product were combined and the acetone was distilled off in vacuum. The pH of the concentrate was adjusted to 3.5-4.0 value by 15% sulphuric acid, then it was extracted 3×250 ml of ethyl acetate. 40 ml of deionized water was added to the combined ethyl acetate extract, then the pH was adjusted to 7.5-8.0 value by 1M sodium hydroxide. After 15 min stirring the aqueous and ethyl acetate phases were separated, then the ethyl acetate solution was extracted with 2×40 ml of deionized water as it was written before. Then the combined alkaline aqueous solution was concentrated to 50 ml volume and chromatographed on a column filled with 600 ml of Diaion HP20 (Mitsubishi Co., Japan) non ionic adsorbent resin (diameter of the column: 3.8 cm, height of the resin bed; 53 cm). The column was washed with 600 ml of deionized water, then eluted with acetone-deionized water mixtures, where the concentration of acetone was increased in 5% steps, collecting 50 ml fractions. The eluate was analysed by TLC method given in the Example 1. Pravastatin was eluted from the column by an acetone-deionized water mixture containing 15% of aceton. Fractions containing pravastatin as single component were combined and the solution was concentrated in vacuum to 150 ml volume. Subsequently, 0.6 g of charcoal was added to the concentrated aqueous solution and pravastatin was clarified at room temperature for 1 hour. Then the charcoal was filtered and the filtrate was lyophilised. The resulting 6.5 g of lyophilised pravastatin was crystallized twice from a mixture of ethanol and ethyl acetate. The precipitate was filtered and washed with 20 ml of ethyl acetate and 20 ml of n-hexane, and dried in vacuum at room temperature. Thus 4.6 g of chromatographically pure pravastatin was obtained.
- A spore suspension was prepared with 5 ml of sterile distilled water from the surface of a 10 days old, soluble starch agar slant culture, as described in Example 1, of Micromonospora echinospora ssp. echinospora IDR-P5 [NCAIM (P) B 001272] strain—being able for the 6β-hydroxylation of compactin acid sodium salt—and the obtained spore suspension was used to inoculate 100 ml of inoculum medium TI sterilized in a 500 ml Erienmeyer flask. Composition of the medium TI was also described in Example 1. The inoculated medium was shaken on a rotary shaker (250 r.p.m., 2.5 cm amplitude) for 3 days at 28° C., then 5 ml aliquots of the developed culture were transferred into 100-100 ml of bioconversion medium TT/1 sterilized in 500 ml Erlenmeyer flasks for 25 min at 121° C. Composition of the medium TT/1 is described In Example 4. Flasks were shaken on a rotary shaker (250 r.p.m. 2.5 cm amplitude) for 3 days at 25° C., then 10-10 mg of compactin substrate (compactin acid sodium salt) was added in sterile filtered aqueous solution into the cultures, then the fermentation was continued for 168 hours.
- At the end of the bioconversion the pravastatin content of the fermentation broth was determined by an HPLC method. At this time the average pravastatin concentration was 40 μg/ml.
- The fermentation, substrate feeding and bioconversion were carried out with strain IDR-P6, [NCAIM (P) B 001273] of Micromonospora megalomicea ssp. nigra as it was written in Example 5. The pravastatin content of the fermentation broth was determined by an HPLC method. At the end of the bioconversion the pravastatin content of the broth was 50 μg/ml.
- 5 ml aliquots of an inoculum culture of strain IDR-P4 [NCAIM (P) B 001271] of Micromonospora purpurea prepared as described in Example 1 were used to seed 100-100 ml of TT/14 medium dispensed in 500 ml Erienmeyer flasks and sterilezed for 25 min at 121° C.
Composition of medium TT/14 Potato starch 5.0 g Glucose 25.0 g Yeast extract (GISTEX) 15.0 g Pepton 15.0 g CaCO3 1.0 g in 1000 ml of tap water - The pH of the bioconversion medium was adjusted to 7.0 before sterilization.
- Flasks were shaken on a rotary shaker (250 r.p.m., 2.5 cm amplitude) for 3 days. The substrate feeding, the bioconversion and determination of the pravastatin content were carried out as described in Example 5. At the end of the bioconversion the pravastatin content of the fermentation broth was 40 μg/ml.
- The fermentation, substrate feeding and bioconversion were carried out with strain IDR-P7, [NCAIM (P) B 001274] of Micromonospora rosaria as it was written in Example 1. At the end of the bioconversion 350 μg/ml pravastatin was measured in the fermentation broth by HPLC method.
Claims (4)
1-7. (canceled)
8. A microbial process for the preparation of the compound of formula (I)
from a compound of the general formula (II)
wherein R stands for an alkali metal or ammonium ion, by the submerged culturing of a suitable bacterial strain which is able to 6β-hydroxylate a compound of formula (II) under aerobic conditions and by the separation and purification of the compound of formula (I) formed in the course of the bioconversion comprising the steps of
a) cultivating a suitable bacterial strain which is able to 6β-hydroxylate a compound of formula (II)—wherein R is as defined above to a compound of the formula (I)—at 25-32° C. on a nutrient medium containing available carbon and nitrogen sources and mineral salts, thereafter
b) feeding the substrate to be transformed into a developing culture, then
c) hydroxylating the substrate until finishing of the bioconversion, then
d) separating the compound of formula (I) from the culture broth and, if desired, purifying the same.
9. A process as claimed in claim 1, wherein the bacterial strain has the 6β-hydroxylate characteristics of Micrononospora.
10. A process as claimed in claim 1, wherein the bacterial strain has the ability to 6β-hydroxylate the compound of formula (II) into Pravastatin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/014,658 US20050124051A1 (en) | 1999-07-12 | 2004-12-16 | Hydroxylation of compactin to pravatatin by micromonospora |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9902352A HUP9902352A1 (en) | 1999-07-12 | 1999-07-12 | Process for producing pravastatin by microbiological way |
HUP9902352 | 1999-07-12 | ||
US10/030,726 US6905851B1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin pravastatin by micromonospora |
PCT/HU2000/000066 WO2001004340A1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin to pravastatin by micromonospora |
US11/014,658 US20050124051A1 (en) | 1999-07-12 | 2004-12-16 | Hydroxylation of compactin to pravatatin by micromonospora |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2000/000066 Continuation WO2001004340A1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin to pravastatin by micromonospora |
US10/030,726 Continuation US6905851B1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin pravastatin by micromonospora |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050124051A1 true US20050124051A1 (en) | 2005-06-09 |
Family
ID=89998701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/030,726 Expired - Fee Related US6905851B1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin pravastatin by micromonospora |
US11/014,658 Abandoned US20050124051A1 (en) | 1999-07-12 | 2004-12-16 | Hydroxylation of compactin to pravatatin by micromonospora |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/030,726 Expired - Fee Related US6905851B1 (en) | 1999-07-12 | 2000-06-29 | Hydroxylation of compactin pravastatin by micromonospora |
Country Status (32)
Country | Link |
---|---|
US (2) | US6905851B1 (en) |
EP (3) | EP1327689A1 (en) |
JP (2) | JP4531315B2 (en) |
KR (2) | KR100479837B1 (en) |
CN (2) | CN1590555A (en) |
AP (1) | AP1405A (en) |
AT (1) | ATE243262T1 (en) |
AU (2) | AU773633B2 (en) |
BG (1) | BG65109B1 (en) |
BR (1) | BR0013156A (en) |
CA (2) | CA2379015A1 (en) |
CZ (2) | CZ297009B6 (en) |
DE (1) | DE60003424T2 (en) |
DK (1) | DK1190087T3 (en) |
ES (1) | ES2200891T3 (en) |
HR (1) | HRP20020028B1 (en) |
HU (1) | HUP9902352A1 (en) |
IL (2) | IL147583A0 (en) |
IS (1) | IS2138B (en) |
MX (1) | MXPA02000356A (en) |
NO (1) | NO20020119L (en) |
NZ (1) | NZ516563A (en) |
OA (1) | OA12150A (en) |
PL (2) | PL353493A1 (en) |
PT (1) | PT1190087E (en) |
RU (2) | RU2235780C2 (en) |
SK (2) | SK285726B6 (en) |
TR (1) | TR200200726T2 (en) |
UA (1) | UA67854C2 (en) |
WO (2) | WO2001004340A1 (en) |
YU (1) | YU2002A (en) |
ZA (1) | ZA200200273B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9800046A (en) | 1998-02-18 | 1999-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Process for obtaining of HMG-CoA reductase inhibitors of high purity |
HUP9902352A1 (en) * | 1999-07-12 | 2000-09-28 | Gyógyszerkutató Intézet Kft. | Process for producing pravastatin by microbiological way |
MXPA02005283A (en) | 1999-11-30 | 2003-10-06 | Biogal Gyogyszergyar | Process for recovering statin compounds from a fermentation broth. |
PL364929A1 (en) | 1999-12-14 | 2004-12-27 | Biogal Gyogyszergyar Rt. | Novel forms of pravastatin sodium |
CZ20031166A3 (en) * | 2000-10-05 | 2004-04-14 | Biogal Gyogyszergyar Rt | Pravastatin sodium salt that is substantially free of pravastatin lactone and epi-pravastatin as well as composition based thereon |
JP3236282B1 (en) * | 2000-10-16 | 2001-12-10 | 三共株式会社 | How to purify pravastatin |
DE60218822T2 (en) * | 2001-02-09 | 2007-07-12 | Unilever N.V. | FOODS CONTAINING SOY PROTEIN AND STATIN |
JP2003026634A (en) * | 2001-07-17 | 2003-01-29 | Mercian Corp | Method for producing pravastatin sodium salt |
US6716615B2 (en) | 2002-02-27 | 2004-04-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase |
EP1452602A1 (en) * | 2003-02-25 | 2004-09-01 | Antibiotic Co., | Method for production of pravastatin by fermentation |
CN1244688C (en) | 2003-07-09 | 2006-03-08 | 上海天伟生物制药有限公司 | Microbe and process for preparing pravastatin sodium |
US7425644B2 (en) | 2003-11-24 | 2008-09-16 | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság | Method of purifying pravastatin |
MY161108A (en) * | 2008-02-06 | 2017-04-14 | Biocon Ltd | Fermentation medias and processes thereof |
RU2522806C1 (en) * | 2012-11-27 | 2014-07-20 | Федеральное государственное бюджетное учреждение науки Центр "Биоинженерия" Российской академии наук | Improved method of purification of pravastatin |
JP6441599B2 (en) * | 2014-07-14 | 2018-12-19 | 合同酒精株式会社 | Production method of pravastatin |
CN114031496A (en) * | 2021-11-30 | 2022-02-11 | 广东蓝宝制药有限公司 | Preparation method of high-purity pravastatin 1,1,3, 3-tetramethylbutylamine |
CN114133331A (en) * | 2021-12-10 | 2022-03-04 | 广东蓝宝制药有限公司 | Method for recovering and obtaining high-purity pravastatin ester |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346227A (en) * | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4537859A (en) * | 1981-11-20 | 1985-08-27 | Sankyo Company, Limited | Process for preparing 3-hydroxy-ML-236B derivatives known as M-4 and M-4' |
US5179013A (en) * | 1987-02-02 | 1993-01-12 | Sankyo Company, Limited | Cytochrome P-450 enzymes |
US5942423A (en) * | 1995-06-07 | 1999-08-24 | Massachusetts Institute Of Technology | Conversion of compactin to pravastatin by actinomadura |
US6682913B1 (en) * | 1999-02-03 | 2004-01-27 | Institute For Drug Research Ltd. | Microbial process for preparing pravastatin |
US6756507B2 (en) * | 1999-12-17 | 2004-06-29 | Ranbaxy Laboratories Limited | Process for the preparation of sodium salts of statins |
US6905851B1 (en) * | 1999-07-12 | 2005-06-14 | Ivax Drug Research Institute | Hydroxylation of compactin pravastatin by micromonospora |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5810572A (en) | 1981-07-07 | 1983-01-21 | Sankyo Co Ltd | Ml-236b derivative and its preparation |
JPS59175450A (en) * | 1983-03-24 | 1984-10-04 | Sankyo Co Ltd | Ml-236b derivative |
JPH06253853A (en) * | 1993-03-09 | 1994-09-13 | Asahi Chem Ind Co Ltd | Modified dna containing macrolide antibiotic substance biosynthetic gene |
US6043064A (en) * | 1993-10-22 | 2000-03-28 | Bristol-Myers Squibb Company | Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof |
JPH0889277A (en) * | 1994-09-28 | 1996-04-09 | Taisho Pharmaceut Co Ltd | Production of 12-hydroxy-6-o-alkylerythromycin and its homologue |
JPH08149986A (en) * | 1994-09-28 | 1996-06-11 | Taisho Pharmaceut Co Ltd | Production of 12-hydroxy-6-o-alkylerythromycin and its analog |
SI20072A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | PROCEDURE OF PREPARATION OF INHIBITORS OF HMG-CoA REDUCTASE |
-
1999
- 1999-07-12 HU HU9902352A patent/HUP9902352A1/en unknown
-
2000
- 2000-06-29 AU AU58355/00A patent/AU773633B2/en not_active Ceased
- 2000-06-29 EP EP03075550A patent/EP1327689A1/en not_active Withdrawn
- 2000-06-29 BR BR0013156-3A patent/BR0013156A/en not_active Application Discontinuation
- 2000-06-29 CN CNA2004100493556A patent/CN1590555A/en active Pending
- 2000-06-29 WO PCT/HU2000/000066 patent/WO2001004340A1/en active IP Right Grant
- 2000-06-29 IL IL14758300A patent/IL147583A0/en not_active IP Right Cessation
- 2000-06-29 DK DK00944121T patent/DK1190087T3/en active
- 2000-06-29 CZ CZ20020119A patent/CZ297009B6/en not_active IP Right Cessation
- 2000-06-29 US US10/030,726 patent/US6905851B1/en not_active Expired - Fee Related
- 2000-06-29 KR KR10-2002-7000475A patent/KR100479837B1/en not_active IP Right Cessation
- 2000-06-29 YU YU2002A patent/YU2002A/en unknown
- 2000-06-29 CN CN00811127A patent/CN1399686A/en active Pending
- 2000-06-29 AT AT00944121T patent/ATE243262T1/en not_active IP Right Cessation
- 2000-06-29 UA UA2002010326A patent/UA67854C2/en unknown
- 2000-06-29 DE DE60003424T patent/DE60003424T2/en not_active Expired - Fee Related
- 2000-06-29 OA OA1200200015A patent/OA12150A/en unknown
- 2000-06-29 NZ NZ516563A patent/NZ516563A/en unknown
- 2000-06-29 PT PT00944121T patent/PT1190087E/en unknown
- 2000-06-29 ES ES00944121T patent/ES2200891T3/en not_active Expired - Lifetime
- 2000-06-29 AP APAP/P/2002/002404A patent/AP1405A/en active
- 2000-06-29 TR TR2002/00726T patent/TR200200726T2/en unknown
- 2000-06-29 MX MXPA02000356A patent/MXPA02000356A/en active IP Right Grant
- 2000-06-29 EP EP00944121A patent/EP1190087B1/en not_active Expired - Lifetime
- 2000-06-29 RU RU2002103376/13A patent/RU2235780C2/en not_active IP Right Cessation
- 2000-06-29 SK SK49-2002A patent/SK285726B6/en unknown
- 2000-06-29 CA CA002379015A patent/CA2379015A1/en not_active Abandoned
- 2000-06-29 JP JP2001509543A patent/JP4531315B2/en not_active Expired - Fee Related
- 2000-06-29 PL PL00353493A patent/PL353493A1/en not_active Application Discontinuation
- 2000-07-11 JP JP2001508931A patent/JP2003528576A/en active Pending
- 2000-07-11 CA CA002373544A patent/CA2373544A1/en not_active Abandoned
- 2000-07-11 PL PL00364872A patent/PL364872A1/en unknown
- 2000-07-11 EP EP00950379A patent/EP1198448A4/en not_active Withdrawn
- 2000-07-11 CZ CZ2002127A patent/CZ2002127A3/en unknown
- 2000-07-11 AU AU63492/00A patent/AU6349200A/en not_active Abandoned
- 2000-07-11 SK SK61-2002A patent/SK612002A3/en unknown
- 2000-07-11 KR KR1020027000486A patent/KR20020060150A/en not_active Application Discontinuation
- 2000-07-11 WO PCT/US2000/019384 patent/WO2001003647A2/en not_active Application Discontinuation
- 2000-07-11 IL IL14758800A patent/IL147588A0/en unknown
-
2002
- 2002-01-10 NO NO20020119A patent/NO20020119L/en not_active Application Discontinuation
- 2002-01-10 HR HR20020028A patent/HRP20020028B1/en not_active IP Right Cessation
- 2002-01-11 IS IS6227A patent/IS2138B/en unknown
- 2002-01-11 ZA ZA200200273A patent/ZA200200273B/en unknown
- 2002-01-14 BG BG106302A patent/BG65109B1/en unknown
-
2004
- 2004-05-13 RU RU2004114667/13A patent/RU2004114667A/en not_active Application Discontinuation
- 2004-12-16 US US11/014,658 patent/US20050124051A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346227A (en) * | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4448979A (en) * | 1980-06-06 | 1984-05-15 | Sankyo Company, Limited | ML-236B Derivatives |
US4537859A (en) * | 1981-11-20 | 1985-08-27 | Sankyo Company, Limited | Process for preparing 3-hydroxy-ML-236B derivatives known as M-4 and M-4' |
US5179013A (en) * | 1987-02-02 | 1993-01-12 | Sankyo Company, Limited | Cytochrome P-450 enzymes |
US5942423A (en) * | 1995-06-07 | 1999-08-24 | Massachusetts Institute Of Technology | Conversion of compactin to pravastatin by actinomadura |
US6682913B1 (en) * | 1999-02-03 | 2004-01-27 | Institute For Drug Research Ltd. | Microbial process for preparing pravastatin |
US20060281155A1 (en) * | 1999-02-03 | 2006-12-14 | Antonia Jekkel | Microbial process for preparing pravastatin |
US6905851B1 (en) * | 1999-07-12 | 2005-06-14 | Ivax Drug Research Institute | Hydroxylation of compactin pravastatin by micromonospora |
US6756507B2 (en) * | 1999-12-17 | 2004-06-29 | Ranbaxy Laboratories Limited | Process for the preparation of sodium salts of statins |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6905851B1 (en) | Hydroxylation of compactin pravastatin by micromonospora | |
JP2003528576A5 (en) | ||
US5153124A (en) | Hydroxyl-ml-236b derivatives, their preparation and use | |
US4421687A (en) | Macbecin derivatives | |
US4421688A (en) | Macbecin derivatives | |
AU633826B2 (en) | Bu-3420t antitumor antibiotic | |
GB2106111A (en) | Macbecin derivatives and their production | |
CA1210350A (en) | Antibiotic complex producing bacterial culture | |
JPH1171323A (en) | New decomposed phosphoglycolipid antibiotic substance and its production | |
US5272174A (en) | Hydroxy-ML-236B derivatives, their preparation and use | |
HU225936B1 (en) | Hydroxylation of compactin to pravastatin by micromonospora | |
JPH0771480B2 (en) | New microorganism | |
JPH0463677B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |